Research and Development Projects in Ayurveda
1. At a Glance
- Ayurgyan Scheme is the Ministry of Ayush's flagship Central Sector Scheme (since 2021-22) channelling R&D funds into Ayurveda via three components: CME, Research & Innovation (R&I), and Ayurveda Biology Integrated Health Research (ABIHR) [S1][S2].
- Relevant for UPSC because it intersects GS-II (Health/Schemes), GS-III (S&T, IPR, Indigenous knowledge) and AYUSH-sector policy questions.
2. Why in the News
- 17 March 2026 PIB release: 16 R&D projects in Ayurveda sanctioned under Ayurgyan's R&I and ABIHR components over FY 2022-23 to FY 2024-25; ABIHR alone supported 11 drug-development/validation projects (2 in FY24, 4 in FY25, 5 in FY26) [S1].
3. Background & Evolution
- 2014: Independent Ministry of AYUSH carved out (previously a department under MoHFW) [S2].
- 2021-22: Ayurgyan Scheme launched as a Central Sector Scheme with two original components — CME and R&I [S1][S2].
- 2023-24: Third component ABIHR added to push high-end translational research [S1][S2].
- Parallel institutional pillar: Central Council for Research in Ayurvedic Sciences (CCRAS) operates 30 institutes/centres nationwide [S2].
4. Core Static Facts
- Type: Central Sector Scheme (100% Union funding) [S1].
- Implementing Ministry: Ministry of Ayush [S1].
- Apex Research Council: CCRAS — 30 institutes/centres [S2].
- Components (3): 1. Capacity Building & CME in Ayush 2. Research & Innovation (R&I) in Ayush — extra-mural clinical, fundamental, pharmaceutical, literary, medicinal-plant research [S2]. 3. ABIHR (added 2023-24) — safety/efficacy evidence, drug development & standardisation, pharmacokinetics/pharmacodynamics, high-end clinical trials [S2].
- Output (2022-25): 16 R&D projects sanctioned under R&I + ABIHR; 11 ABIHR drug projects through FY26 [S1].
- Sister initiatives: National AYUSH Mission (Centrally Sponsored, supports States) [S3]; AGNI initiative for Ayurveda practitioners' innovations [S4]; PRAGATI-2024 by CCRAS for industry-academia collaboration [S5].
5. Multi-Dimensional Analysis
Scientific / Technological - ABIHR explicitly funds pharmacokinetic/pharmacodynamic studies, toxicity evaluation, high-end clinical trials — moves Ayurveda research from classical literature toward evidence-based modern validation [S2]. - Integrates Ayurveda with biology disciplines, enabling cross-fertilisation with DBT/DST research models [S2].
Administrative / Governance - Central Sector design: scheme is not State-specific; eligible institutions across India apply for grants [S1]. - Extra-mural funding model: bypasses ministry-run labs to draw in universities, scientific institutes, hospitals [S2].
Economic / Industry - Supports drug development and standardisation — preconditions for Ayurveda exports and pharmacopoeial compliance [S2]. - Complements PRIP scheme (Pharma-MedTech ~₹11,000 cr) by feeding validated Ayush drug pipelines [S6].
Social / Health - Builds clinical evidence base needed for integration of Ayush into public health delivery and insurance coverage. - CME component upgrades Ayurveda teacher/practitioner quality (e.g., AIIA-run CME programmes under Ayurgyan) [S7].
6. Recent Developments (last 12-18 months)
- 17 Mar 2026: PIB — 16 R&D projects across 3 years; ABIHR ramp-up (5 projects in FY 2025-26) [S1].
- FY 2023-24: ABIHR component operationalised as third pillar [S1].
- AIIA (All India Institute of Ayurveda) ran three CME programmes for Ayurveda teachers under Ayurgyan [S7].
- CCRAS PRAGATI-2024 launched for industry-Ayurveda partnerships [S5].
7. Prelims Hooks
- Ayurgyan is a Central Sector Scheme, not Centrally Sponsored [S1].
- Ayurgyan launched in 2021-22; ABIHR component added in 2023-24 [S1].
- Three components: CME, R&I, ABIHR [S1].
- Implementing ministry: Ministry of Ayush (independent ministry since 2014) [S1].
- Apex research council for Ayurveda: CCRAS, with 30 institutes/centres [S2].
- ABIHR focus areas include pharmacokinetics, pharmacodynamics, toxicity evaluation, high-end clinical trials [S2].
- 16 R&D projects supported under R&I + ABIHR during FY 2022-23 to 2024-25 [S1].
- ABIHR drug-development projects: 2 (FY24), 4 (FY25), 5 (FY26) [S1].
- AGNI = initiative for promoting innovations by Ayurveda practitioners [S4].
- PRAGATI-2024 = CCRAS initiative to shape Ayurveda's future via industry collaboration [S5].
- National AYUSH Mission (NAM) is the State-facing Centrally Sponsored Scheme — distinct from Ayurgyan [S3].
8. Mains Relevance
- GS-II: Government policies & interventions for health sector.
- GS-III: Science & Technology — indigenisation, IPR over traditional knowledge.
- Probable stems: 1. "Critically examine the role of the Ayurgyan Scheme in mainstreaming evidence-based Ayurveda research in India." 2. "Validation of traditional medicine through modern scientific methodology is essential for global acceptance. Discuss with reference to ABIHR." 3. "Differentiate between the National AYUSH Mission and the Ayurgyan Scheme in terms of design and objectives."
9. Related Topics to Study Next
- National AYUSH Mission (NAM) — sister Centrally Sponsored Scheme for States [S3].
- CCRAS, CCRH, CCRYN, CCRUM — four AYUSH research councils.
- AIIA, New Delhi — apex Ayurveda institute; CME delivery node [S7].
- AGNI initiative — practitioner-led innovation database [S4].
- PRIP Scheme (Dept of Pharmaceuticals) — complementary pharma R&D push [S6].
- TKDL (Traditional Knowledge Digital Library) — IPR-defensive instrument.
- WHO Global Centre for Traditional Medicine, Jamnagar — international anchor for Ayurveda.
- Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H) — standards body.
10. Common Errors / Trap Areas
- Confusing Ayurgyan (Central Sector) with National AYUSH Mission (Centrally Sponsored) — different funding pattern and beneficiaries [S1][S3].
- Misdating ABIHR — it was added in 2023-24, not at scheme inception in 2021-22 [S1].
- Counting components as two (CME + R&I); correct number is three after ABIHR addition [S1].
- Attributing CCRAS to Ministry of Health & Family Welfare — it is under the Ministry of Ayush [S2].
- Treating AGNI as a scheme; it is an initiative under CCRAS for practitioner innovations [S4].
11. Sources
- [S1] Research and Development Projects in Ayurveda (PIB, 17 Mar 2026) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2241124®=3&lang=2 — (tier: 1)
- [S2] Ministry of Ayush Promotes Scientific Research Through Apex Research Councils (PIB) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2149775 — (tier: 1)
- [S3] National AYUSH Mission (PIB) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2079080®=3&lang=2 — (tier: 1)
- [S4] 'AGNI' Initiative to Promote Innovations by Ayurveda Practitioners (PIB) — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=1978802 — (tier: 1)
- [S5] CCRAS Launches PRAGATI-2024 (PIB) — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2021953 — (tier: 1)
- [S6] PRIP Scheme call for proposals (PIB) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2173970 — (tier: 1)
- [S7] AIIA CME Programmes under Ayurgyan Scheme (PIB) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2166544®=3&lang=2 — (tier: 1)